BioXcel Therapeutics is trading at $0.15, with a -16.81% change, after its August 27, 2026 Chapter 11 filing and proposed sale of substantially all assets to Teva.
- Reuters confirmed the bankruptcy filing; regulatory documents detail Teva’s $57.5 million upfront offer plus up to $67.5 million in contingent payments.
- Bankruptcy and the court-supervised asset sale continue pressuring equity holders.
- Teva’s bid remains subject to higher offers and court approval.